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The transcriptional activity of the integrated HIV provirus is dependent on the chromatin organization of the viral promoter
and the transactivator Tat. Tat recruits the cellular pTEFb complex and interacts with several chromatin-modifying enzymes,
including the histone acetyltransferases p300 and PCAF. Here, we examined the interaction of Tat with activation-dependent
histone kinases, including the p90 ribosomal S6 kinase 2 (RSK2). Dominant-negative RSK2 and treatment with a small-molecule
inhibitor of RSK2 kinase activity inhibited the transcriptional activity of Tat, indicating that RSK2 is important for Tat function.
Reconstitution of RSK2 in cells from subjects with a genetic defect in RSK2 expression (Coffin-Lowry syndrome) enhanced Tat
transactivation. Tat interacted with RSK2 and activated RSK2 kinase activity in cells. Both properties were lost in a mutant Tat
protein (F38A) that is deficient in HIV transactivation. Our data identify a novel reciprocal regulation of Tat and RSK2 function,
which might serve to induce early changes in the chromatin organization of the HIV LTR.
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INTRODUCTION
The early phase of HIV transcription is characterized by the
absence of the viral transactivator Tat and a block in viral
transcription elongation [1]. During this phase, basal activity of
the viral promoter is controlled by the local chromatin environ-
ment, cellular transcription factors that bind to cis-acting elements
in the viral promoter, and the processivity of the recruited RNA
polymerase II (reviewed in [2]). Although inefficient, basal
promoter activity is thought to result in a few full-length viral
transcripts and synthesis of Tat. Tat dramatically increases the
production of full-length transcripts and renders HIV transcription
independent of the chromatin environment at the site of integra-
tion [3]. Among its functions, Tat recruits the positive transcrip-
tion elongation factor b (pTEFb) to the TAR element, an RNA
stem loop structure at the 59 termini of nascent HIV transcripts
(reviewed in [4]). The arginine-rich motif in Tat (amino acids
49–57) binds to a bulge structure in TAR, while the Tat
transactivation domain (amino acids 1–48) associates with the
cyclinT1 component in pTEFb [5]. CyclinT1 exists as a complex
with cyclin-dependent kinase 9 (CDK9), which hyperphosphor-
ylates the C-terminal domain of RNA polymerase II, increasing its
ability to elongate efficiently on the viral template [6,7].
Various histones modifications occur during transcriptional
activation (reviewed in [8]), and some are specifically linked to
transcriptional elongation (reviewed in [9,10]). Histone acetylation
and methylation correlate with transcriptional activity of the HIV
promoter [11,12,13,14,15]. Tat interacts with several transcrip-
tional cofactors that have intrinsic histone acetyltransferase (HAT)
activity, including Tip60, p300/CBP, PCAF, TAFII250, human
GCN5 [16,17,18,19,20,21,22,23], and is itself acetylated by p300/
CBP, PCAF and human GCN5 [21,24,25,26].
Histones can also be phosphorylated in response to several
cellular processes. In particular, the rapid and transient mitogen-
induced phosphorylation of serine 10 in the tail of histone H3 has
been coupled to the transcriptional activation of immediate-early
response genes [27]. This phosphorylation event is an early marker
in mitogen-induced gene activation and can control subsequent
histone acetylation events [28,29]. However, for some genes
histone phosphorylation and acetylation are independent events
[30,31]. Activation-dependent mammalian kinases with intrinsic
histone H3 kinase activity include ribosomal S6 protein kinase 2
(RSK2), mitogen- and stress-activated protein kinase 1 (MSK1)
and IkB kinase alpha (IKKa) [32,33,34,35].
RSK2 is one of four RSK serine-threonine kinases that are
activated through the mitogen-activated protein kinase (MAPK)
signal transduction pathway. RSK family members are unusual
because they contain two distinct kinase domains that are both
catalytically functional. [36] The N-terminal kinase domain
phosphorylates downstream targets and is activated through
a sequential phosphorylation cascade involving 3-phosphoinosi-
tide-dependent protein kinase 1 (PDK1), the C-terminal kinase
domain of RSK2 and ERK1/2 (reviewed in [37]). Inactivating
mutations and truncations in the RSK2 gene are responsible for
Coffin-Lowry syndrome (CLS), which is characterized by severe
mental retardation and progressive skeletal deformations
[38,39,40,41]. Fibroblasts from CLS patients were found deficient
in histone phosphorylation induced by treatment with epidermal
growth factor (EGF), indicating that RSK2 is relevant for mitogen-
induced histone phosphorylation [32]. However, more recent
results show a prominent role of MSK1/2 in mitogen- and stress-
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phorylates transcriptional coactivators and transcription factors,
including CBP, CREB and c-fos [43,44,45,46]. The transcription
factor ATF4 was identified as a preferred substrate for RSK2 and
was linked to the skeletal abnormalities in CLS patients [47].
In this study, we examined the role of histone kinases in Tat
transactivation. We have observed that Tat increases phosphor-
ylation of histone H3 associated with the HIV promoter. Our
findings identify a novel role of Tat as an adaptor and activator of
RSK2 in cells and show that RSK2 activity is required for full
transactivation of Tat.
RESULTS
Histone H3 hyperphosphorylation at the HIV LTR in
the presence of Tat
To study histone H3 phosphorylation of the HIV promoter, we
performed chromatin immunoprecipitation (ChIP) studies with
antibodies specific for phosphorylated serine 10 in histone H3
(Figure 1A). We used extracts from Jurkat T cells containing an
integrated HIV promoter which were either infected with
a lentiviral vector expressing the green fluorescent protein (GFP)
or Tat [3]. Immunoprecipitations were followed by radioactive
PCR with primers specific for the HIV LTR, the c-fos, or the b-
globin genes. We observed that HIV LTR-specific sequences were
enriched in immunoprecipitates from Tat-expressing cells, in-
dicating that histone H3 phosphorylation at the HIV promoter
was increased in the presence of Tat. No difference between GFP-
and Tat-expressing cells was detected for the c-fos or b-globin
genes, demonstrating that the observed increase was specific for
Tat and the HIV promoter.
Kinase-deficient RSK2 suppresses Tat
transactivation
To examine the influence of histone kinases on Tat transactiva-
tion, kinase-deficient RSK2, MSK1 or IKKa with known
dominant-negative properties were transiently overexpressed in
Jurkat 1G5 T cells containing an integrated HIV promoter
luciferase construct. Coexpression of kinase-deficient RSK2, but
not of kinase-deficient MSK1 or IKKa, inhibited the activity of
coexpressed Tat on the HIV promoter (Figure 1B). Basal LTR
activity was unaffected when kinase-deficient RSK2 was trans-
fected in the absence of Tat, indicating that the effect of RSK2
is specific for Tat. Expression of kinase-deficient RSK2 had no
effect on Tat expression as confirmed by western blot analysis
(Figure 1C). Accordingly, kinase-deficient RSK2 did not affect the
activity of the cytomegalovirus (CMV) immediate-early promoter
that was driving Tat expression in these experiments (Figure 1D).
In addition, no effect was observed on the activity of a Gal4-
CDK9 fusion protein that transactivates the 5xUAS promoter,
excluding the possibility that RSK2 regulates the activity of the
Tat-associated kinase pTEFb (Figure 1E).
RSK2 expression is required for Tat transactivation
Next, we examined Tat transactivation in a fibroblast cell line
from a patient with CLS. No RSK2 protein was detected by
western blot analysis (Figure 2A). We used nuclear microinjections
to introduce synthetic Tat, the HIV LTR luciferase reporter,
and a GFP expression plasmid into these cells. Coinjection of
an RSK2-expressing plasmid increased Tat transactivation
levels fivefold, demonstrating that RSK2 synergizes with Tat
to activate the HIV promoter (Figure 2B). Kinase-deficient
RSK2 had no effect, indicating that the catalytic activity of
RSK2 is required for synergy with Tat (Figures 2B). No dominant-
negative effect of kinase-deficient RSK2 was observed due to the
lack of endogenous RSK2 in CLS cells. RSK2 did not affect the
5xUAS promoter activated by the Gal4-VP16 transactivator,
indicating that the effect of RSK2 is specific for Tat transactivation
(Figure 2C).
Figure 1. Role of histone kinases in Tat transactivation. (A) Chromatin
immunoprecipitation analysis of Jurkat T cells containing an integrated
HIV promoter in the absence or presence of Tat. Immunoprecipitations
were performed with a-phospho-histone H3 antibodies (serine 10)
followed by radioactive PCR with primers specific for the HIV LTR, the c-
fos, or the b-globin genes. (B) Jurkat 1G5 cells containing an integrated
HIV LTR luciferase construct were transiently transfected with Tat/FLAG
(25 ng) and kinase-deficient (KD) kinase expression vectors (200 ng). (C)
Western blot analysis of cellular lysates from 293 cells cotransfected
with the indicated expression plasmids. (D) Transfection of CMV
luciferase (25 ng) with the KD RSK2 expression plasmid (200 ng) in
Jurkat cells. (E) Transfection of 5xUAS luciferase and Gal4-CDK9 (20 ng)
with the KD RSK2 expression plasmid (200 ng) in Jurkat cells. Values are
means6SEM of three experiments.
doi:10.1371/journal.pone.0000151.g001
RSK2 and Tat
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Tat is a nuclear protein, while RSK2 shuttles between the
cytoplasm and the nucleus [48,49]. To determine if the two
proteins interact physically in cells, we transfected Cos7 cells with
RSK2/HA and Tat/FLAG, and immunoprecipitated the nuclear
extracts with a-FLAG agarose. RSK2 coimmunoprecipitated with
Tat in cells transfected with RSK2 and Tat expression vectors, but
no signal was obtained when RSK2 or Tat was expressed alone
(Figure 3A). The same was observed when RSK2 was immuno-
precipitated with HA-specific antibodies and recovery of Tat was
analyzed (data not shown). Tat also coimmunoprecipitated with
endogenous RSK2 in Tat-expressing, but not vector-transfected,
Cos7 cells (Figure 3B) and in Jurkat T cells infected with an HIV-
Figure 2. Superinduction of Tat activity in CLS fibroblasts. (A) Western blot analysis of cellular extracts of fibroblasts from a patient with CLS and
control human fibroblasts. (B) Nuclear microinjection of CLS fibroblasts with synthetic Tat (amino acids 1–72), the HIV LTR luciferase reporter, a CMV-
GFP expression plasmid, and either the empty vector, an RSK2 expression construct, or a plasmid expressing kinase-deficient RSK2. Values are
means6SEM of five experiments. (C) Coinjection of the 5xUAS luciferase reporter, a plasmid expressing the Gal4-VP16 transactivator and CMV-GFP
with either the RSK2-expressing plasmid or the vector alone. Values are means6SEM of three experiments.
doi:10.1371/journal.pone.0000151.g002
Figure 3. Interaction of Tat and RSK2 in vivo and in vitro. (A) Coimmunoprecipitation of RSK2 with Tat in nuclear extracts from Cos7 cells
cotransfected with RSK2/HA and Tat/FLAG. One representative experiment of five is shown. (B) Coimmunoprecipitation of Tat with endogenous RSK2
in nuclear extracts from Cos7 cells transfected with Tat/FLAG. Immunoprecipitations were performed three times with a-RSK2 or a-CD71 antibodies as
a control. (C) Coimmunoprecipitation of Tat with endogenous RSK2 in Jurkat T cells transduced with an HIV-based lentiviral vector expressing Tat/
FLAG from the HIV LTR and in uninfected Jurkat T cells. One experiment of two is shown. (D) In vitro binding of GST-Tat (amino acids 1–86) or Tat
mutants to full-length recombinant RSK2. Western blotting of RSK2 before (Input) and after GST binding is shown. One representative experiment of
three is shown. (E) Coimmunoprecipitation of RSK2 with wild type Tat, but not with mutant TatF38A, in nuclear extracts of cotransfected Cos7 cells.
Results were confirmed in three independent experiments.
doi:10.1371/journal.pone.0000151.g003
RSK2 and Tat
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natural promoter, the HIV LTR (Figure 3C). No RSK2- or Tat-
specific signals were obtained after immunoprecipitation with
a control antibody (Figure 3B) or with sepharose beads alone
(Figure 3C).
To further examine the Tat/RSK2 interaction, recombinant
Tat (amino acids 1–86) fused to the C-terminus of glutathione-S-
transferase (GST) was incubated with full-length human RSK2
isolated from insect cells. After pulldown with glutathione-
sepharose, RSK2 copelleted with GST-Tat 1–86, demonstrating
direct interaction between both proteins (Figure 3D, lane 1).
RSK2 did not bind to GST, confirming that RSK2 binds the Tat
component in the fusion protein (Figure 3D, lane 8). No binding
was observed when only the N-terminal 35 amino acids of Tat were
included in the reaction, indicating that these residues are not
involved in RSK2 binding (Figure 3D, lane 2). Accordingly, binding
was not reduced when RSK2 was incubated with a mutant Tat
protein lacking amino acids 1–36 (Figure 3D, lane 3). However,
deletion of amino acids 1–48 significantly reduced binding to RSK2,
indicating that amino acids 37–48 in Tat are involved in RSK2
binding (Figure 3D, lane 4). Amino acids 37–48 correspond to the
core region in Tat, which is necessary for Tat transactivation
(reviewed in [50]). To confirm that this region is involved in RSK2
binding, we tested binding of RSK2 to three full-length GST-Tat
fusion proteins with alanine-scanning mutations in the core region
(Figure 3D, lanes 5, 6, 7). Binding to RSK2 was reduced to the
greatest extent by mutation of amino acids 36–39, followed by
mutations of amino acids 40–43 and amino acids 44–48. Thus, the
critical interacting residues lie within amino acids 36–39 in Tat.
Next, we mutated phenylalanine 38 (F38) to alanine within the
full-length FLAG-tagged Tat expression vector used in coimmu-
noprecipitation experiments. After cotransfection of wild type
Tat/FLAG or TatF38A/FLAG with RSK2/HA into Cos7 cells,
coimmunoprecipitation of RSK2 was only detected for wild type,
and not for the mutant, Tat protein (Figure 3E). The difference in
detection of RSK2 in the presence of Tat is a variation in RSK2
expression rather than in RSK2 translocation, since the same
pattern of RSK2 detection was observed in cytoplasmic extracts
from the same experiment (not shown). The variation of Tat
expression is unique to this experiment (Figure 3E).
Transcriptional synergy with RSK2 is lost in TatF38A
F38 is a highly conserved residue in Tat, and alanine substitution
was shown to abrogate Tat transcriptional activity [51]. Others
reported normal transactivation of a TatF38 mutant (TatF38L) in
transfection assays, but impaired viral growth when the mutation
was introduced into infectious HIV [52,53]. We transfected wild
type Tat or TatF38A into Jurkat 1G5 cells and found that the
mutation abrogated Tat transactivation of the integrated HIV
promoter (Figure 4A). To test whether the mutation affected
synergy with RSK2, we cotransfected Tat- and RSK2-expressing
constructs together with the HIV LTR luciferase reporter into CLS
cells. While RSK2 synergized with wild type Tat, no synergy was
observed with TatF38A, supporting the model that RSK2
suppports Tat transactivation via binding to F38 (Figure 4B).
Again, kinase-deficient RSK2 had no effect, confirming that RSK2
catalytic activity is required for synergy with Tat (Figure 4B).
Activation of the N-terminal RSK2 kinase activity by
Tat
To examine the Tat-interacting domain in RSK2, we performed
binding studies using biotinylated synthetic Tat protein (amino
acids 1–72) and in vitro synthesized radioactive RSK2. We also
tested two RSK2 deletion mutants spanning amino acids 1–360
and 375–740, respectively. After pull-down with streptavidin-
agarose, full-length RSK2 and RSK2 1–360 interacted in a dose-
dependent manner with Tat, indicating that the Tat-interacting
domain lies in the N-terminus of RSK2 (Figure 5A). No signal was
detected when RSK2 was incubated with streptavidin-agarose
alone, excluding unspecific binding in this assay.
Amino acids 1–360 harbor the N-terminal kinase domain,
which mediates substrate phosphorylation by RSK2. To deter-
mine if Tat binding affects the kinase activity of RSK2, we
transfected Cos7 cells with Tat- or TatF38A-expressing constructs
and performed standard S6 peptide phosphorylation assays after
immunoprecipitation of endogenous RSK2. Expression of wild
type, but not mutant Tat increased the kinase activity of endo-
genous RSK2 threefold (Figure 5B), as did epidermal growth
factor (EGF), a natural stimulus of RSK2 kinase activity (not
shown).
Activation of RSK2 by Tat was further examined by western
blot analysis. After mitogenic stimulation, serine 227 (S227) in
RSK2 is phosphorylated, an event that correlates with substrate
phosphorylation by RSK2 [54]. We cotransfected RSK2/HA-
and Tat/FLAG-expressing constructs in Cos7 cells and examined
cell lysates with antibodies specific for phospho-S227 in RSK2.
Phosphorylation in RSK2 was enhanced by wild type Tat, but not
TatF38A, indicating that Tat binding to RSK2 is required for the
Figure 4. Transcriptional activity of TatF38A. (A) Transfection of
indicated amounts of Tat- or TatF38A-expressing constructs in Jurkat
1G5 cells using the DEAE-dextran method. (B) Cotransfection of
indicated amounts of Tat or TatF38A with the HIV LTR luciferase
(200 ng) and wild type or kinase-deficient RSK2 (200 ng) in CLS cells.
Values are means6SEM of five experiments for wild type and three
experiments for mutant Tat.
doi:10.1371/journal.pone.0000151.g004
RSK2 and Tat
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(Figure 5C). Reprobing of the membrane with HA- and FLAG-
specific antibodies showed similar levels of RSK2/HA and both
Tat proteins throughout the experiment (Figure 5C).
To test whether Tat recruits RSK2 to the HIV promoter, we
performed ChIP assays with a-phospho-S227 antibodies. Chro-
matin solutions were extracted from Jurkat T cells containing
a single integrated latent HIV genome. Following TNF-a treat-
ment, HIV transcription is activated in these cells and Tat is
produced. The DNA immunoprecipitated along with phospho-
S227 was analyzed by PCR with primers specific for the HIV
promoter or for the cellular c-fos gene. After induction with
TNF-a, the HIV LTR-specific sequence was enriched in the
immunoprecipitated fraction, demonstrating that phospho-RSK2
is recruited to the HIV LTR in vivo (Figure 5D). TNF-a treatment
alone did not activate S227 phosphorylation in the absence of Tat,
suggesting that the recruitment or the activation of RSK2 at the
HIV promoter occurred specifically in the presence of Tat (data
not shown). No enrichment was observed for the c-fos-specific
sequence or when a-phospho-S227 antibodies were omitted from
the reaction (Figure 5D).
Suppression of HIV transcription by FMK, a novel
inhibitor of RSK2
Recently, a structural bioinformatics-based approach was used to
design selective inhibitors of RSK1, 2, and 4, including the
compound FMK, which at 1 or 10 mM inactivates RSK1 and
RSK2 in mammalian cells [55]. Treatment of Jurkat 1G5 cells
with FMK suppressed Tat-dependent HIV transcription in a dose-
dependent manner after transfection of the Tat vector (Figure 6A).
Importantly, FMK did not suppress the transcriptional activity of
the Gal4-CDK9 fusion protein, confirming that the effects of RSK2
on Tat transactivation are not mediated by pTEFb (Figure 6B).
To examine the effect of FMK on HIV infection, we generated
infectious HIV particles using a molecular clone of HIVNL4-3 that
contains the GFP open reading frame in place of the viral nef gene
[56]. This clone also contains a frameshift mutation in the viral env
gene, restricting analysis to a single infection cycle. Viral particles
were pseudotyped with VSV-G. Jurkat T cells were incubated with
viral supernatant, washed, and treated with FMK (10 mM) or
DMSO alone. FMK reduced HIV gene expression two- to
threefold, as measured by GFP expression, but had no effect on
GFP expression in cells infected with an HIV-based lentiviral vector
expressing GFP from the elongation factor 1a (EF-1a) promoter
(Figures 6C and D). These data indicate that the RSK2 kinase
activity regulates viral gene expression during HIV infection.
DISCUSSION
This study shows that RSK2 is a novel regulator of Tat
transactivation, a conclusion supported by three independent
observations. First, a dominant-negative form of RSK2, but not of
other histone kinases, inhibited Tat transactivation. This effect was
specific for Tat since no effect was observed on basal promoter
activity of the HIV LTR or on the Tat-independent CMV
promoter. Second, cells from CLS patients, which lack RSK2,
exhibited a transcriptional defect. Ectopic expression of RSK2, but
not of a catalytically inactive mutant, enhanced Tat transactiva-
tion in CLS cells, demonstrating that the kinase activity of RSK2 is
important for Tat transactivation. In contrast, RSK2 overexpres-
sion in CLS cells slightly inhibited the transcriptional activity of
the VP16 transactivator, demonstrating that RSK2 targets Tat
specifically and that its overexpression does not induce general cell
hyperactivation. Third, the RSK inhibitor FMK suppressed Tat
transactivation and HIV gene expression. This effect was specific
for HIV transcription, since no effect was observed on the
infection with control viral vectors, in which GFP expression was
driven by the cellular EF-1a promoter.
A Tat mutant (F38A) that does not bind RSK2 exhibited
a transcriptional defect that cannot be attributed exclusively to
RSK2. F38 lies in the core domain of Tat, which is involved in
binding of other transcriptional cofactors, including cyclinT1 and
PCAF [5,22,23]. Interestingly, kinase-deficient RSK2 and the
RSK inhibitor FMK had no effect on the transcriptional activity of
Figure 5. Activation of RSK2 by Tat. (A) Autoradiography of radioactive
in vitro synthesized RSK2 proteins before (Input) and after binding to
biotinylated synthetic Tat (amino acids 1–72) or to beads alone.
Increasing amounts of in vitro translated RSK2 were included in the
binding reaction. (B) Kinase assay of endogenous RSK2 immunopreci-
pitated from Cos7 cells transfected with wild type Tat/FLAG, TatF38A/
FLAG, or empty vector. Values are means6SEM of four experiments. (C)
Western blotting of nuclear extracts isolated from Cos7 cells
cotransfected with RSK2/HA and Tat/FLAG or with RSK2/HA and Tat
F38A/FLAG constructs. Densitometric quantification of the phospho-
S227-specific bands was performed using the NIH Image software. (D)
Chromatin immunoprecipitation analysis of the Jurkat T cell line A2,
latently infected with an HIV-based lentiviral vector expressing Tat/
FLAG from the HIV LTR after treatment with TNF-a. At indicated time
points, cells were harvested and immunoprecipitations were performed
in duplicate with a-phospho-S227 antibodies followed by PCR with
primers specific for the HIV LTR or the c-fos gene.
doi:10.1371/journal.pone.0000151.g005
RSK2 and Tat
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of pTEFb. This finding excludes the possibility that RSK2
regulates Tat transactivation through pTEFb.
The observation that Tat activates the kinase activity of RSK2 is
unexpected and shows an important novel function of Tat. The
enzymatic activity of RSK2 is regulated by sequential phosphor-
ylation events. Phosphorylation by ERK1/2 displaces an inhibi-
tory a-helix from the substrate-binding region of the C-terminal
kinase domain of RSK2 and activates its kinase activity [57,58].
This leads to autophosphorylation of serine 386 (S386) in the
linker region between the kinase domains, which recruits and
activates PDK1 [59]. PDK1 phosphorylates S227 in the N-
terminal kinase domain, the final step in the phosphorylation
cascade, and induces substrate phosphorylation.
We have shown that this final step is activated by Tat. It is not
clear whether Tat binding leads to immediate phosphorylation of
S227 or involves the classical MAPK-induced activation cascade.
Interestingly, ERK1 expression might be decreased in cells
expressing Tat [60]. Direct activation of RSK2 by Tat,
independently of upstream activation signals, could therefore
compensate for a decrease in ERK1 expression and signaling
during HIV infection. We and others observed that U0126, an
inhibitor of MAPK/ERK kinase (MEK), the kinase upstream of
ERK, had no effect on Tat transactivation, supporting the notion
that Tat targets RSK2 directly (data not shown; [61]). Moreover,
FMK, a direct inhibitor of RSK2 kinase activity, suppressed Tat
transactivation in a dose-dependent manner. FMK selectively
inhibits the C-terminal kinase domain and targets a reactive
cysteine that, together with a threonine ‘‘gatekeeper,’’ controls
access of FMK to the ATP binding pocket [55]. A recent study
found MAP kinase p38a activated through direct binding by the
adaptor protein transforming growth factor-b-activated protein
kinase 1-binding protein 1 (TAB1) in the absence of upstream
signals [62]. It was proposed that TAB1 binding induced
a conformational change in p38a, which activated its kinase
activity and enhanced the level of kinase autophosphorylation.
One possibility is that Tat through binding to the N-terminal
kinase domain, which does not exhibit substantial intrinsic
autophosphorylation activity [58], alters the structural conforma-
tion of RSK2 and stimulates the autophosphorylation activity of
the C-terminal kinase domain, leading to phosphorylation of
S386 and subsequently S227. In addition, by direct binding to the
N-terminal kinase domain, Tat could activate S227 phosphoryla-
tion through an unknown mechanism.
Figure 6. Suppression of HIV transcription by FMK, a small-molecule inhibitor of RSK2. (A) Transient transfection of Jurkat 1G5 cells, containing an
integrated HIV LTR luciferase construct, with Tat/FLAG (20 and 200 ng). Transfected cells were treated with indicated amounts of FMK or DMSO for
18 h. Values are mean6SEM of four experiments. (B) Cotransfection of Jurkat T cells with 5xUAS luciferase and Gal4-CDK9 (20 ng) and subsequent
treatment with FMK at indicated concentrations. Values are means6SEM of four experiments. (C) GFP expression in Jurkat T cells infected with HIVNL4-
3 containing the GFP open reading frame in place of the viral nef gene or with an HIV-based lentiviral vector expressing GFP from the heterologous
EF-1a promoter. After overnight infection, cells were treated with FMK or DMSO for 36 h. Values are means6SEM of three experiments. *p=0.002 (t
test). (D) GFP expression in one representative experiment performed with HIV GFP or HIV (EF-1a) GFP virus.
doi:10.1371/journal.pone.0000151.g006
RSK2 and Tat
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enhanced in Tat-expressing T cells. In addition, we show that
activated RSK2 is recruited to the HIV promoter in vivo, where it
can target histones. We and others have previously shown that Tat
also recruits the HAT activity of PCAF via its acetylated lysine 50
[14,22,23,63]. Since at some promoters acetylation of lysine 14 in
histone H3 – mediated by PCAF - is enhanced when serine 10 is
phosphorylated, the two functions of Tat can be expected to
synergize in the stimulation of HIV transcription. However, in our
experiments the positive effect of RSK2 on Tat transactivation was
observed on integrated as well as nonintegrated LTR promoter
templates, which may indicate that RSK2 targets additional
substrates besides histones. Future experiments will address the
role of RSK2 in the phosphorylation of histone H3 or other known
RSK2 substrates at the HIV promoter, including CBP, CREB,
c-fos and ATF4.
MATERIAL AND METHODS
Cells and plasmids
Cos7, HeLa, 293, and Jurkat cells (American Type Culture
Collection), Jurkat 1G5 cells (AIDS Research and Reference
Reagent Program), and CLS fibroblasts (Coriell Institute for
Medical Research, Camden, NJ) were cultured under standard cell
culture conditions. Jurkat 1G5 cells were transiently transfected
with the DEAE-dextrane technique, and luciferase activity was
measured 20 h later (Promega).
Jurkat cells were stably infected with lentiviral vectors expressing
Tat/FLAG [56,64]. Constructs encoding N-terminal HA-tagged
wild type and dominant-negative RSK2 (K100A) were provided
by M. Greenberg (Harvard Medical School, Boston, Massachu-
setts, USA) [45], dominant-negative IKKa (K44M) by W. Greene
and A. O’Mahony (Gladstone Institute of Virology and Immu-
nology, San Francisco, California, USA) [65], dominant-negative
MSK1 (R102A) and HA-tagged RSK2 and deletion mutants by
M. Frodin (Department of Clinical Biochemistry, Glostrup
Hospital, 2600 Glostrup, Denmark) [59,66]. NotI/XhoI fragments
from these RSK2 vectors were blunted and subcloned into the
EcoRV site of pcDNA3.1 (Invitrogen) for in vitro transcription/
translation (Promega). GST-Tat 1–86 and 1–48 were obtained
from the AIDS Research and Reference Reagent Program. All
other GST-Tat deletion constructs were a gift from Q. Zhou and
D. Chen (Department of Molecular and Cell Biology, University
of California, California, USA) [67]. The 5xUAS construct, in
which 5 x Gal4 binding sites were cloned upstream of the TK
promoter [68], was provided by B. Spiegelman (Dana-Farber
Cancer Institute and Department of Cell Biology, Harvard
Medical School, Boston, Massachusetts, USA) and the Gal4-
CDK9 construct by M. Peterlin (Department of Medicine,
Rosalind Russell Medical Research Center, University of
California, San Francisco, California,USA) [69]. Full-length Tat
(101 amino acids) bearing a C-terminal FLAG tag [25] and the
LTR luciferase construct [70] have been described. The Tat-
FLAG construct served as template for site-directed mutagenesis
(Stratagene) to generate the F38A mutation. The CMV luciferase
construct was generated by cloning the luciferase gene as
a HindIII/BamHI fragment obtained from pGL2 Basic (Promega)
into pcDNA3.1 (Invitrogen). The CMV-GFP construct was
purchased from Clontech.
ChIP Assays
Jurkat cells, 24 h after transduction with lentiviral vectors
encoding either Tat or GFP and Jurkat clone A2 containing
a single integrated latent HIV minigenome induced with
TNF-a (10 ng/ml; Biosource) were fixed with 1% formaldehyde,
partially digested with micrococcal nuclease (Roche) and sonicated
as described [71]. Precleared chromatin solutions were incubated
overnight at 4uC with 1 mg of rabbit a-phospho-histone H3 (S10;
Upstate Biotechnology) or 5 mg of rabbit a-phospho-S227 (Santa
Cruz Biotechnology). Immune complexes were collected with
protein A-sepharose preblocked with sonicated salmon sperm
DNA (Upstate Biotechnology). Formaldehyde cross-links were
reverted by incubating the samples at 65uC overnight in the
presence of 200 mM NaCl. One-tenth of the immunoprecipitated
DNA was used in PCR reactions using primers previously
described [64].
Viral infection experiments
Jurkat T cells infected with lentiviral vectors expressing Tat/
FLAG or GFP used in coimmunoprecipitation experiments have
been described [64]. For studies with the RSK2 inhibitor FMK,
Jurkat cells were infected with a molecular clone of HIV
containing the GFP open reading frame in place of nef [56].
FMK is a pyrrolopyrimidine that contains a fluoromethylketone.
Minimal lentiviral vectors driving GFP expression from a heterol-
ogous promoter (EF-1a) served as a control (pHR’-EF-1a/GFP)
[72]. Viral particles were pseudotyped with vesicular stomatitis
virus glycoprotein (VSV-G). All vectors and protocols to generate
lentiviral particles were provided by D. Trono (EPFL SV-DO,
Lausanne, Switzerland). Jurkat T cells were incubated overnight
with lentiviral particles at a theoretical multiplicity of infection
(m.o.i.) of 0.5 in 24-well plates. Cells were repeatedly washed and
resuspended in fresh medium containing FMK (1 or 10 mM) or
DMSO alone. Viral infection was monitored 36 h later by flow
cytometric analysis using a Calibur FACScan (Beckton Dickinson).
Nuclear microinjections and transfections of CLS
cells
Subconfluent CLS fibroblasts were grown on Cellocate coverslips
(Eppendorf) and were microinjected at room temperature with an
automated injection system (Carl Zeiss) or a micromanipulator/
transjector (Eppendorf). The medium was buffered during the
microinjection by adding 20 mM HEPES buffer. Samples were
prepared as a 20 ml injection mix containing synthetic Tat (30 ng/
ml) [23,64] and the LTR luciferase (100 ng/ml) and CMV-GFP
(50 ng/ml) constructs together with the CMV-RSK2 expression
construct or the empty vector (each 200 ng/ml). Live cells were
examined on a Zeiss Axiovert or a Nikon Eclipse TE300
microscope to determine the number of GFP-positive cells. Four
hours after injection, cells were washed in cold PBS and processed
for luciferase assays (Promega).
For transfections, subconfluent CLS fibroblasts in six-well plates
were transfected using Lipofectamine reagent (Invitrogen) and
Tat-expressing plasmid (0.3 and 3 ng), HIV LTR luciferase
reporter (200 ng) and RSK2-expressing constructs or empty vector
(each 200 ng). Cells were harvested twenty-four hours after
transfections and equal amounts of cellular extract (as measured
by protein content) processed for luciferase assays (Promega).
Coimmunoprecipitation and western blot analysis
Cos7 cells (3610
5) were transfected with Tat- and RSK2-
expressing plasmids (6 mg) with Lipofectamine reagent (Invitro-
gen). Twenty-four hours after transfection, nuclear extracts were
prepared in hypotonic buffer (HB) as described [43]. Equal
amounts of nuclear extracts were precleared with protein A- or G-
sepharose (Amersham Pharmacia Biotech) that had been blocked
with 50 mg/ml BSA in HB for 1 h at 4uC. Precleared nuclear
RSK2 and Tat
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(Roche), or a-RSK2 (Santa Cruz Biotechnology) antibodies and
protein A- or G-sepharose overnight at 4uC in HB supplemented
with 120 mM NaCl. Pellets were washed five times in HB
supplemented with 120 mM NaCl, resuspended in Laemmli
buffer, and analyzed by western blot with a-FLAG, a-HA or a-
RSK2 antibodies.
Tat and endogenous RSK2 were coimmunoprecipitated from
cellular extracts isolated from Jurkat cells or Jurkat cells infected
with a lentiviral vector expressing Tat/FLAG under the control of
the HIV LTR [64]. Western blot analysis with phospho-S227-
specific antibodies (Santa Cruz Biotechnology) was performed as
described [59].
Kinase assays
Nuclear extracts from Cos7 cells transfected with Tat/FLAG, Tat
F38A/FLAG, or vector alone were immunoprecipitated with a-
RSK2 antibodies as described above. Immunoprecipitates were
washed three times in HB supplemented with 120 mM NaCl and
once in kinase assay buffer [43]. Kinase assays were performed
with a standard S6 kinase protocol (Upstate Biotechnology).
In vitro binding assays
Constructs encoding wild type RSK2 or deletion mutants were
subjected to in vitro transcription/translation in the presence of
20 mCi [
35S]-methionine (Amersham Pharmacia Biotech) using
the TNT T7-coupled reticulocyte lysate system (Promega).
Biotinylated synthetic Tat protein [23,64], immobilized to
streptavidin-sepharose, was incubated with 0.5 or 1.5 mlo f
reticulocyte lysate containing radioactive RSK2 proteins in HB
buffer supplemented with 120 mM NaCl described above.
Binding reactions were incubated for 10 min at 30uC, washed
three times in binding buffer containing 1 M KCl, and analyzed
by SDS-PAGE. The gel was fixed, amplified (Amersham
Pharmacia Biotech), and exposed to BioMax MR film (Kodak).
GST fusion proteins were expressed in the BL21 strain of
Escherichia coli and purified with glutathione-sepharose as described
[6]. Bound proteins were eluted with 25 mM glutathione (Sigma),
dialyzed (50 mM Tris, pH 8.0, 20 mM NaCl, 0.5% NP-40, 5 mM
DTT, 50 mg/ml AEBSF, 15% glycerol), and protein concentra-
tions were measured with the RC DC protein assay (Bio-Rad) and
verified after SDS-PAGE by Coomassie staining or western blot
analysis.
For in vitro binding studies, equal amounts of GST proteins
(1 mg/ml) were immobilized to glutathione-sepharose beads that
had been blocked with 50 mg/ml BSA in binding buffer (20 mM
Hepes, pH 7.9, 1% Triton, 0.5% NP-40, 200 mM KCl, 0.1%
BSA, 2 mM DTT, protease inhibitor cocktail). After three washes
in EBC/DTT/SDS (50 mM Tris, pH 8.0, 20 mM NaCl, 0.5%
NP-40, 5 mM DTT, 50 mg/ml AEBSF, 0.075% SDS, protease
inhibitor cocktail) and one wash in binding buffer, the beads were
incubated with 200 ng of human recombinant RSK2 (Upstate
Biotechnology). Bead-coupled proteins were washed three times in
binding buffer containing 1 M KCl and boiled in Laemmli buffer,
and supernatants were analyzed by western blot analysis with a-
RSK2 antibodies (Santa Cruz Biotechnology).
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